Former FDA Acting Commissioner Friedman
Executive Summary
Pharmaceutical Research & Manufacturers of America Chief Medical Officer for Biomedical Preparedness Michael Friedman, MD, is named CEO of City of Hope cancer research and treatment center (Los Angeles), effective May 1. PhRMA's biomedical preparedness team now reports to Chief Scientist-Biomedical Preparedness and Lilly VP-Scientific Affairs Gail Cassell, PhD. Friedman was also serving as Pharmacia's senior VP-medical public policy. The firm recently completed its merger with Pfizer. Friedman was FDA deputy commissioner for operations from 1995 to 1999 and headed the agency as acting commissioner after the departure of Commissioner Kessler in 1997...
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.